Analysts Set Autolus Therapeutics plc (NASDAQ:AUTL) Target Price at $9.32

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) have received an average recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is $9.32.

Several research firms have recently issued reports on AUTL. Truist Financial lowered their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Wells Fargo & Company lowered their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 21st. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, April 10th.

Autolus Therapeutics Stock Up 3.1%

AUTL stock opened at $1.33 on Friday. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.00. The company has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $2.15. The firm has a market capitalization of $353.97 million, a P/E ratio of -1.10 and a beta of 1.77.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analysts’ expectations of $1.59 million. As a group, analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC lifted its holdings in shares of Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock worth $62,000 after buying an additional 6,081 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock valued at $56,000 after buying an additional 8,479 shares during the period. Barclays PLC increased its stake in shares of Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after buying an additional 10,866 shares during the period. Jane Street Group LLC purchased a new position in shares of Autolus Therapeutics during the fourth quarter valued at $26,000. Finally, Invesco Ltd. increased its stake in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.